RE:lightening market My understanding is that TFC-1067 for dark spots is put front and center, but the deal includes TFC-1394 as well which I assume targets skin lightening aimed for the asian market. AbbVie licensed the whole library centered around TFC-1067.
If the terms are descent, I appreciate the deal - if not, it's a disaster giving away the current crown juvel for free - again.
I would love a great deal. However, due to the non-disclosure I'm suspicious given the track record. Seems like the market agree with me.
If the R+F deal would have been great, the new AbbVie deal could have been received very positive by the market in terms of a real spike and sustainable much higher share price. The management has put themselves in a weak position and must prove that they are capable, hence the ask for numbers.